Noticias de TEM_US
Noticias del mercado
Últimas noticias sobre TEM_US — 794 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Tempus AI CEO Eric Lefkofsky sells over $16.2 million in company stock
Cathie Wood’s ARK sells Tempus AI stock, buys Veracyte By Investing.com
Historical data tab for Tempus AI, Inc. Tokenized Stock (Robinhood) in USD for download and research
Discover 1 Best Exchanges Offering 1 TEM Markets for Buying, Selling, and Trading Tempus AI, Inc. Tokenized Stock (Robinhood). Get insights on spread, 24-hour trading volume data, and quotes across DEX and CEX platforms.
Comprehensive analysis of Tempus AI, Inc. Tokenized Stock (Robinhood) price dynamics, quarterly returns, and annual trends in dollars. Our detailed research unveils dynamic interconnections between Tempus AI, Inc. Tokenized Stock (Robinhood) and the US dollar, providing valuable insights based on current data.
Guardant Suits Against Tempus AI Clear Dismissal Bids
A Delaware federal judge has refused to throw out litigation accusing Tempus AI Inc. of infringing Guardant Health Inc. patents covering technology used to analyze cancer-related genetic data and help guide testing and treatment.
A Delaware federal judge has refused to throw out litigation accusing Tempus AI Inc. of infringing Guardant Health Inc. patents covering technology used to analyze cancer-related genetic data and help guide testing and treatment.
Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]
Página 14 de 40